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S U M M A R Y
Background: Leishmaniasis is a neglected tropical disease, endemic in many worldwide foci including the
Middle East. Several outbreaks have occurred in the Middle East over the past decades, mostly related to
war-associated population migration. With the start of the Syrian war, the frequency and magnitude of
these outbreaks increased alarmingly. We describe the epidemiology of Leishmania infection in Lebanon
and the most recent outbreak relevant to the Syrian war.
Methods: We reviewed all leishmaniasis cases reported to the Epidemiologic Surveillance Department at
the Lebanese Ministry of Public Health between 2001 and the ﬁrst quarter of 2014. The demographics
and distribution of Syrian refugees in Lebanon were linked to reports of new Leishmania cases.
Results: In total, 1033 new cases of leishmaniasis were reported in 2013 compared to a previous annual
number in the range of 0–6 cases. The majority of cases reported in 2013 involved Syrian refugees and
their relevant areas of concentration.
Conclusions: This new outbreak of leishmaniasis in Lebanon is the ﬁrst of its kind for more than a decade.
The sudden increase in Leishmania cases in Lebanon in 2013 is attributed to the increasing numbers and
wide distribution of Syrian refugees in Lebanon. This serves as an example of the risks associated with
military conﬂicts and the ability of communicable diseases to cross borders.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Leishmaniasis is caused by the obligate intracellular parasites of
Leishmania species and is transmitted by the female phlebotomine
sandﬂy. Classiﬁed as a neglected tropical disease, leishmaniasis has
focal areas of prevalence in tropical and subtropical regions and the
Mediterranean Basin.1 Depending on the endemic species of
Leishmania, human and/or animal reservoirs maintain the
propagation of the parasite. Some species like Leishmania tropica
are anthroponotic, having solely human hosts. Other species like
Leishmania major are zoonotic, exhibiting animal reservoirs.2
The clinical manifestations of leishmaniasis tend to occur
months after exposure and can be one of three presentations* Corresponding author. Tel.: +961 1 375375.
E-mail addresses: ab00@aub.edu.lb, ama114@aub.edu.lb (A.R. Bizri).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).depending on host and parasite characteristics.1 Cutaneous
leishmaniasis (CL) is characterized merely by skin manifestations
including papules and nodules that may ulcerate. Although these
skin lesions tend to heal spontaneously, they may result in
disﬁguring and stigmatizing scars with a considerable impact on
quality of life. Mucocutaneous leishmaniasis (ML) is a consequence
of an untreated cutaneous infection that spreads into adjacent
mucosal surfaces, and these tend not to heal spontaneously. The
most severe and potentially fatal form is visceral leishmaniasis
(VL), which affects internal organs including the bone marrow,
liver, and spleen, and may exhibit a latent form reviving during
states of immunodeﬁciency.1,3,4
No vaccine is available for Leishmania and the only preventative
method is to limit exposure to the vector through vector control,
insect repellents, insecticide-impregnated bed nets, and other
modalities. The traditional approach to the treatment of leishmani-
asis includes amphotericin B or its lipid formulations for visceralciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Reported cases of Leishmania in Lebanon per month from January
2013 through March 2014. The graph shows that cases have continued to occur in
2014 at a high rate relative to the previous years (2001–2012); however, the
number of cases has started to decrease since a peak in December 2013.
Table 1
Distribution of Leishmania cases reported to the Lebanese Ministry of Public Health,
by age group and gender (modiﬁed from http://www.moph.gov.lb).
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several other treatment modalities have been proposed.4,5
According to the World Health Organization (WHO), around
two million cases of Leishmania are reported annually from
88 countries.6 This ﬁgure is believed to be an underestimate of the
true numbers by ﬁve to eight times, since reporting of the disease is
obligatory in only 32 of the 88 endemic countries.6,7 Over the past
decade, the global burden of Leishmania has nearly reduced by
half,8 but its incidence is still on the rise in several regions, mainly
the Middle East and South America.9
Leishmania is the most important protozoan infection in the
Middle East and North Africa (MENA) region,10,11 where several
risk factors contribute to an increased frequency of infection. The
most signiﬁcant are those associated with wars and population
clustering and relocation, resulting in the exposure of unimmu-
nized individuals to the parasite.6 Among the different countries of
the MENA region, Syria is known to have the highest prevalence of
CL,10 which is often referred to in the area as ‘Aleppo boil’ after
Aleppo, the Syrian city. Recently, owing to different war-related
factors, new outbreaks have been reported by the mass media from
different areas bordering Syria, including Turkey and Iraq.11,12
Leishmaniasis is a mandatory reportable disease in Lebanon, and
the Lebanese Ministry of Public Health (LMOPH) has implemented
active surveillance for leishmaniasis since the beginning of the
Syrian conﬂict.13
In this study, we evaluated the current leishmaniasis situation
in Lebanon in light of the increasing numbers of Syrian refugees in
the country, the fact that Lebanon has adopted an open border
policy with Syria allowing the free ﬂow of refugees, and the
decrease in United Nations (UN) allocated resources coupled with
the limited assets available to the Lebanese government to control
the situation.14 We also revisited the association between war and
Leishmania, and the main challenges faced in the control of this
infection in Lebanon are discussed herein.
2. Methods
Records from the Epidemiological Surveillance Department,
Lebanese Ministry of Public Health (ESDMOH) were reviewed for
cases of leishmaniasis in Lebanon reported between January
2001 and March 2014. All cases reported were reviewed in terms of
area of residence, age and gender, clinical presentation, treatment,
and outcome. As per the LMOPH recommendations, all cases were
diagnosed by the traditional diagnostic techniques of smear,
parasite culture, and histological analysis of skin biopsies obtained
by qualiﬁed physicians assigned to various districts. A case is
classiﬁed as ‘probable’ if the person is showing only clinical signs
without parasitological conﬁrmation, or as ‘conﬁrmed’ after punch
biopsy and parasitological conﬁrmation by a positive smear or
culture.15
Cases affecting Lebanese nationals were also distinguished
from those of Syrian refugees, and the locations of Syrian refugee
tented settlements were reviewed in terms of their distribution
across various Lebanese districts. The number of Syrian refugees
and their distribution all over Lebanon was obtained from the
United Nations Refugee Agency (UNHCR).16
Cases obtained from ESDMOH records were used to draw an
epidemiological map eliciting the distribution of new leishmania-
sis cases across various Lebanese districts, along with the locations
of concentrations of Syrian refugees.
3. Results
Over the 12 years of 2000–2012, an annual number ranging
between 0 and 6 cases of Leishmania infection were reported to the
ESDMOH. In 2013, 1033 cases of Leishmania were reported; 998 cases(96.6%) were identiﬁed among Syrian refugees and the remaining
cases (3.4%) involved both Lebanese nationals and Palestinian
refugees. An additional 217 cases were reported this year (January
through March 2014), of which 208 involved Syrian refugees. As
illustrated in Figure 1, the distribution of leishmaniasis cases per
month showed a peak number in December 2013 (146 cases), with
numbers appearing to decrease thereafter (January through March
2014). Only two nonfatal cases of VL were reported and the remaining
cases were of the cutaneous form. All cases reported to the ESDMOH
were conﬁrmed by biopsy and parasitological examination (smear
and/or culture). The two VL cases were treated successfully with
liposomal amphotericin B, while cases of CL were treated with
intralesional or systemic meglumine antimonate (Glucantime), both
provided free of charge by the LMOPH.
Children and adolescents (less than 20 years of age) were the
most affected age group. Table 1 shows the age distribution of
leishmaniasis cases reported. Less than 10% of cases occurred in
people over 40 years of age. Of note, the distribution of the Syrian
refugee population across the different age groups was not skewed
towards the younger age groups (Figure 2).
The cases were reported from several Lebanese districts, but
Bekaa district had the highest percentage of cases (726 cases,
70.3%), as well as highest incidence among Syrian refugees
(38 cases/100 000). Figure 3 shows two epidemiological maps
representing the distribution of Leishmania infection among the
Figure 2. Distribution of the Syrian refugee population and cases of leishmaniasis
among the different age groups. The graph shows that although a higher frequency
of cases occurred in the younger age groups (<10 years old), these age groups do not
account for the majority of the population. Data on the Syrian refugee population
were obtained from UNHCR.16.
A. Alawieh et al. / International Journal of Infectious Diseases 29 (2014) 115–119 117Lebanese districts and the incidence of leishmaniasis among the
concentrations of Syrian refugees.
In Lebanon, around 985 346 Syrian refugees are registered at
the United Nations Refugee Agency (UNHCR), the majority being in
the Bekaa and North provinces (62%) (Figure 3). They are
distributed all over Lebanon, in more than 540 locations, and
are not restricted to special camps or tented settlements. However,
the Lebanese government has reported that the true number of
Syrian refugees in the country has exceeded one million.16,17
4. Discussion
According to McDowell et al. in 2011, the MENA region reported
0.04 million cases of CL caused by L. tropica, with Syria being theFigure 3. (A) Map showing the distribution of Leishmania cases among the different distr
Leishmania cases reported in 2013. (B) Map showing the incidence of leishmaniasis am
incidence (38 cases/100 000) compared to South area (6 cases/100 000) due to the concen
Lebanon.country with the highest prevalence, and 0.03 million cases of CL
caused by L. major, with Iran being the country with the highest
prevalence.10 Both species, L. major and L. tropica, have been
reported previously to be the major causative agents of Leishmania
in Lebanon and Syria, compared to Leishmania arabica in Saudi
Arabia.18 However, data from the MENA region as well as other
regions of endemic leishmaniasis are an underestimate, especially
given that some countries do not report the various pathological
forms of Leishmania and others do not report at all. For VL, records
of its occurrence are more obscure; the WHO has reported an
estimated number of 875 cases per year from the entire
Mediterranean Area.19
Although leishmaniasis is endemic in Lebanon and has been
reported mainly from the North district, the drastic increase in
number of cases seen during the 2013–2014 period is a call for
concern and a warning for the potential of a future major
outbreak.20,21 Before 2013, the highest number of cases reported
per year was six cases in 2010; hence the Lebanese health care
professionals, facilities, and authorities are unprepared to handle
an outbreak of the disease, especially if it occurs in rural areas
where health care assets are minimal.
The current outbreak in 2013–2014 correlates with the massive
increase in arrival of Syrian refugees.16 Although this outbreak has
predominantly involved the Syrian refugees, cases among Leba-
nese citizens and residents have also been reported. Despite this
strong correlation with the inﬂux of Syrian refugees, and given the
fact that Leishmania is known to occur in some Lebanese regions,
Lebanon may be witnessing a pseudo-outbreak owing to the
increase in surveillance and reporting measures instigated by the
LMOPH with the escalation in the Syrian crisis. Although this
hypothesis is possible, the majority of cases having involved Syrian
refugees and the cases being clustered in their areas of
concentration are strongly against this argument.
The fear of a spread of the infection outside the Syrian refugee
community has driven the LMOPH as well as other relevant
governmental departments to initiate a coordinated campaign toicts of Lebanon: areas along the Syrian–Lebanese border had the highest number of
ong Syrian refugees in different regions of Lebanon: Bekaa area had the highest
tration and high density of Syrian refugees in the Bekaa area compared to southern
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kill the vector, providing free treatment and diagnosis for emerging
cases, distributing medications free of charge to the different
primary care centers, and vigilant monitoring of disease activity.13
Measures taken by the LMOPH have also involved promoting
surveillance measures to ensure disease detection and adequate
treatment of all cases. These measures include training physicians
and health care workers on disease symptoms, raising their index
of suspicion, as well as educating the Lebanese public and Syrian
refugees about the disease symptoms and how to seek medical
advice and treatment. In addition, the ministry has also assigned
new centers for Leishmania detection and treatment in all
Lebanese hospitals, including those in rural areas and near refugee
camps.13 These measures may explain the decrease in disease
occurrence since December 2013, even though the rate of refugee
inﬂux into Lebanon has remained the same.
This new outbreak has raised concerns that the parasite may be
able to form new circles of disease propagation in different foci in
Lebanon, where the vector may ﬁnd a favorable habitat and where
appropriate zoonotic reservoirs are present. One main region of
particular risk is Bekaa district (Figure 3) located on the northeastern
border with Syria, which has had the highest share of leishmaniasis
cases (70.3%) as well as the highest density of Syrian refugees.
Reasons contributing to the higher burden in this area include the
presence of high numbers of Syrian refugees in dense concentrates,
which facilitates the spread of infection. In addition, this area has
environmental conditions similar to those of many Syrian districts
and is also rural and less developed, with limited health care assets.
The age distribution of those infected with Leishmania has been
skewed towards the younger age groups despite the fact that the
reported demographics of the Syrian refugees do not show a higher
population of young vs. older age groups (Figure 2). The increased
frequency of leishmaniasis among the younger Syrian population
cannot simply be explained by higher numbers, but rather by the
fact that older Syrian refugees are more likely to have been
exposed to the disease previously. Such a ﬁnding is very common
in areas of high prevalence where new cases are more predominant
among the youth.22
Several factors contribute to the complexity of the situation in
Lebanon, magnifying the consequences of the outbreak at the
national level. They include: (1) an inﬂux of refugees at a rapid rate,
not allowing the government to cope with their needs; (2) the
inﬁltration of refugees into different regions of Lebanon without
restriction to designated camps; (3) a lack of familiarity of Lebanese
physicians with the manifestations of the disease, leading to a delay
in diagnosis; (4) the absence of well-trained laboratory personnel
required to detect the parasite; and (5) the limited access to
treatment, which is only available at a few designated locations.
The Syrian war-associated outbreaks are not one of a kind in the
Middle East. In Iraq, war and instability between the years
2002 and 2004 were believed to be responsible for the high
occurrence of the disease, ranging between 3000 and 4000 cases a
year.23 A large epidemic occurred during the civil war in Sudan
between 1984 and 1994 in which VL was estimated to have caused
around 100 000 deaths.24 War-associated leishmaniasis outbreaks
in the Middle East have also been reported historically among
foreign troops serving in the area.25–27
Leishmaniasis continues to be endemic in the Middle East
owing to several obstacles preventing proper control. According to
the WHO initiative, the Leishmania control plan consists of (1)
early diagnosis and prompt treatment; (2) vector and reservoir
control, especially for zoonotic forms; (3) population health
education; (4) monitoring of epidemics and early containment;
and (5) management of Leishmania–HIV co-infection.6 Several
challenges have impeded the success of this program in many
endemic areas; the main obstacle is under-reporting and poormonitoring of the disease. CL is among the most under-reported
diseases. The fact that the disease occurs in poor rural areas is a
major reason for under-reporting. Limited access to medical care
and the stigmatizing morbidity associated with CL, make families
tend to hide rather than report the disease.9 The lack of efﬁcient
governmental efforts and poor surveillance contribute to the
spread of infection especially in times of war and political
instability. The media has an important role in reporting war-
associated diseases like Leishmania, as is the case for Syria.28
The absence of an effective vaccine or any preventative drug for
Leishmania adds to the challenge of control and restricts contain-
ment efforts to limiting human exposure to the potential vectors and
vector and reservoir eradication.3,4 In addition, treatment alter-
natives for resistant Leishmania strains are still limited, as most
trials have been poorly designed and reported, resulting in a lack of
evidence for potentially beneﬁcial treatment outcomes.29
The potential global impact of leishmaniasis was emphasized in
2009 during a Leishmania research and policy conference held in
Tunisia to enhance collaborative efforts between the USA and
countries of the Old World with endemic leishmaniasis.10 The
interest of the USA and other developed countries in Leishmania in
the Middle East arises from the possibility of the disease being
imported through immigrants, travelers, troops, reporters, non-
governmental organization (NGO) workers, and even tourists,
contributing to the globalization of this disease. Today, this threat
is now more concerning given the recent outbreaks and status of
instability in the regions endemic for leishmaniasis.
In conclusion, Lebanon is experiencing an outbreak of leishman-
iasis possibly as a result of the Syrian crisis and the inﬂux of refugees.
This should be a solid aide memoire to remind us of the ability of
wars and military conﬂicts to cause and spread disease and infection.
The measures taken by the LMOPH are key and central to any
response, but require the cooperation of other concerned parties to
ensure success. The importance of coordinating efforts among
various governmental departments, international agencies, local
authorities, medical associations, and NGOs is crucial for containing
this or similar outbreaks in Lebanon, or any other country in the
region. With no near end in sight for the Syrian conﬂict, it is of the
utmost importance to emphasize the need for characterizing the
different Leishmania species involved in this outbreak, as well as the
need to conduct risk assessments on the probability of the further
spread of Leishmania to other areas in the immediate future. Of note,
the Syrian conﬂict has also resulted in other major challenges to the
Lebanese and regional health care systems, with concerns about the
spread of other serious infectious diseases. These include poliomy-
elitis, which has recently re-emerged in Syria, and other vaccine-
preventable diseases in Syria.30
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